Prostate Cancer is the most commonly diagnosed cancer in males in the UK. Whilst localised disease can be treated by surgery or radiotherapy (Labrie, 2007; Walsh, 2002) patients presenting with clinically apparent prostate cancer often have metastatic disease. Androgen ablation is the first line treatment for metastatic prostate cancer however, although the disease initially responds to androgen withdrawal almost all patients relapse after a median period of approximately 2 years and become castrate resistant (Tomioka et al., 2007). Docetaxel is currently the only drug which has been found to extend survival in these patients (Petrylak et al., 2004; Tannock et al., 2004). With the development of life extending microtubule targeting agents, including Docetaxel (Di Lorenzo et al., 2007) it has become necessary to investigate the effect of androgen ablation on the new regimens. In this study the consequence of targeting the microtubules with Docetaxel in prostate cancer is investigated, including how this interacts with current therapeutic regimes.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:500893 |
| Date | January 2008 |
| Creators | Stockley, Jacqueline |
| Publisher | University of Newcastle Upon Tyne |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.252 seconds